A judge in the US has approved the sale of Purdue Pharma’s consumer health business Avrio, part of the bankruptcy proceedings related to the drugmaker’s proposed $10 billion settlement of ...

WEST LAFAYETTE — With Will Berg's elite size, Purdue basketball found a miniature role for the 7-foot-2 redshirt sophomore center late in the season. Berg, who played in all five of the ...

INDIANAPOLIS — Purdue basketball coach Matt Painter used to give his players two weeks off after the season’s final game before regrouping with individual meetings about their futures.

Purdue basketball has become a staple in the Sweet 16 men's NCAA Tournament round. Under coach Matt Painter, the program has reached the regional semifinal round six times since 2017 and the ...

INDIANAPOLIS (WISH) — It was heartbreak for Purdue at Lucas Oil Stadium. With the game tied with two seconds left, Houston had the ball under the basket. Houston’s Milos Uzan inbounded the ...

Purdue basketball lost a heartbreaker to Houston in the Sweet 16, with Houston hitting a game-winning shot in the final second. Despite the loss, Purdue is poised for a strong run next season ...

Purdue Pharma and its controlling Sackler family have offered a new settlement to resolve lawsuits over their involvement in the opioid epidemic, raising the payout from the Sacklers to $6 billion.

The Houston Cougars and Purdue Boilermakers put on a show in the Sweet 16 on Friday night. Sadly for Purdue, a beautiful inbounds play from Houston ended with a bucket with just 0.9 seconds left ...

Kelvin Sampson, Milos Uzan and No. 1 Houston knocked off Trey Kaufman-Renn and No. 4 Purdue, 62-60, in the Sweet 16 men's March Madness on Saturday night to earn a spot in the Elite Eight.

INDIANAPOLIS — Houston spent time this week practicing an inbound play that coach Kelvin Sampson thought his team might need against Purdue. Milos Uzan, the third option, ran it to perfection.

It's becoming an annual rite of passage in college basketball. As the transfer portal opens amid the NCAA Tournament, consternation abounds over how different — and perhaps not for the better ...

Investment bankers say large pharma and biotech deals are stalling as executives grapple with mercurial White House economic ...